494 related articles for article (PubMed ID: 23036818)
1. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
[TBL] [Abstract][Full Text] [Related]
2. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
[TBL] [Abstract][Full Text] [Related]
3. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
[TBL] [Abstract][Full Text] [Related]
4. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
6. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
7. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection of Lactococcus lactis-displayed HA2 subunit against homologous and heterologous influenza A viruses in mice.
Lei H; Peng X; Zhao D; Jiao H; Ouyang J
Arch Virol; 2015 Dec; 160(12):3011-9. PubMed ID: 26358264
[TBL] [Abstract][Full Text] [Related]
9. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
Prabakaran M; Kolpe AB; He F; Kwang J
Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
[TBL] [Abstract][Full Text] [Related]
10. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.
Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y
Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927
[TBL] [Abstract][Full Text] [Related]
11. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
12. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
[TBL] [Abstract][Full Text] [Related]
14. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
15. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection.
Gocník M; Fislová T; Mucha V; Sládková T; Russ G; Kostolanský F; Varečková E
J Gen Virol; 2008 Apr; 89(Pt 4):958-967. PubMed ID: 18343837
[TBL] [Abstract][Full Text] [Related]
16. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
17. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
19. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
20. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
